Managed Access Programs for PKC412, Midostaurin
NCT05219266 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-06-28
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.
Conditions
- FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
- Acute Myeloid Leukemia
- Aggressive Systemic Mastocytosis
- Mast Cell Leukemia
- Systemic Mastocytosis With an Associated Hematologic Neoplasm
Interventions
- DRUG
-
midostaurin
Patients receive midostaurin
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
NCT00035867 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
NCT05363488 ·Status: COMPLETED
-
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01895842 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
NCT01419496 ·Status: COMPLETED
-
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
NCT06303193 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
NCT01324336 ·Status: COMPLETED
-
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
NCT06851065 ·Status: COMPLETED
-
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
NCT00462605 ·Status: COMPLETED ·Phase: PHASE2
-
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
NCT00006213 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
NCT00324194 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346 ·Status: COMPLETED ·Phase: PHASE2
-
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
NCT03686345 ·Status: TERMINATED ·Phase: PHASE2
-
Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia
NCT01150656 ·Status: COMPLETED
-
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Aflibercept in Treating Patients With Myelodysplastic Syndromes
NCT00509249 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Of The Selective PKC-β Inhibitor MS- 553
NCT03492125 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
NCT06979076 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02642965 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
NCT00546377 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
NCT05007860 ·Status: COMPLETED
-
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
NCT05168904 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
NCT01223898 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
NCT07075406 ·Status: COMPLETED
-
A Study of Galunisertib in Participants With Myelodysplastic Syndromes
NCT02008318 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
NCT04263181 ·Status: ACTIVE_NOT_RECRUITING